Cargando…

Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab

BACKGROUND: We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD). METHODS: This retrospective study examined 53 patients with neovascular AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Alice L, Seidensticker, Florian, Schaumberger, Markus, Welge-Lussen, Ulrich, Wolf, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990463/
https://www.ncbi.nlm.nih.gov/pubmed/24748769
http://dx.doi.org/10.2147/OPTH.S58410
_version_ 1782312283128463360
author Yu, Alice L
Seidensticker, Florian
Schaumberger, Markus
Welge-Lussen, Ulrich
Wolf, Armin
author_facet Yu, Alice L
Seidensticker, Florian
Schaumberger, Markus
Welge-Lussen, Ulrich
Wolf, Armin
author_sort Yu, Alice L
collection PubMed
description BACKGROUND: We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD). METHODS: This retrospective study examined 53 patients with neovascular AMD treated with multiple injections of intravitreal ranibizumab. The main outcome measure was the difference in IOP between the frequently-treated study eyes (≥15 injections) and the unfrequently-treated fellow control eyes (≤ five injections). Patients were divided into three study groups: group I (35 patients with 15 to 19 injections); group II (15 patients with 20 to 29 injections); and group III (three patients with ≥30 injections). The IOP was measured by Goldmann applanation tonometry 4 weeks after the last injection of intravitreal ranibizumab. For statistical analysis, the IOP was then correlated with the number of ranibizumab injections. RESULTS: Among the frequently-treated study eyes, the mean IOP was 13.68±2.91 mmHg (range, 8 to 20 mmHg). The unfrequently-treated fellow control eyes had a mean IOP of 13.45±3.09 mmHg (range, 9 to 25 mmHg). There was no significant correlation of the IOP difference between the study and control eyes with the number of ranibizumab injections (correlation coefficient 0.77; P=0.583). For each of groups I, II, and III, the difference in mean IOP between the study and control eyes was nonsignificant (P>0.05). There was also no significant association of the IOP difference between the study and control eyes with the number of ranibizumab injections for each group (P=0.391). CONCLUSION: Our study did not find an increased IOP in frequently-ranibizumab-treated eyes when compared to unfrequently-treated fellow control eyes. Further studies with a greater sample size are needed to evaluate whether an increased number of ranibizumab injections is associated with IOP changes.
format Online
Article
Text
id pubmed-3990463
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39904632014-04-18 Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab Yu, Alice L Seidensticker, Florian Schaumberger, Markus Welge-Lussen, Ulrich Wolf, Armin Clin Ophthalmol Original Research BACKGROUND: We wanted to determine whether multiple injections of intravitreal ranibizumab was associated with an elevated intraocular pressure (IOP) in patients treated for neovascular age-related macular degeneration (AMD). METHODS: This retrospective study examined 53 patients with neovascular AMD treated with multiple injections of intravitreal ranibizumab. The main outcome measure was the difference in IOP between the frequently-treated study eyes (≥15 injections) and the unfrequently-treated fellow control eyes (≤ five injections). Patients were divided into three study groups: group I (35 patients with 15 to 19 injections); group II (15 patients with 20 to 29 injections); and group III (three patients with ≥30 injections). The IOP was measured by Goldmann applanation tonometry 4 weeks after the last injection of intravitreal ranibizumab. For statistical analysis, the IOP was then correlated with the number of ranibizumab injections. RESULTS: Among the frequently-treated study eyes, the mean IOP was 13.68±2.91 mmHg (range, 8 to 20 mmHg). The unfrequently-treated fellow control eyes had a mean IOP of 13.45±3.09 mmHg (range, 9 to 25 mmHg). There was no significant correlation of the IOP difference between the study and control eyes with the number of ranibizumab injections (correlation coefficient 0.77; P=0.583). For each of groups I, II, and III, the difference in mean IOP between the study and control eyes was nonsignificant (P>0.05). There was also no significant association of the IOP difference between the study and control eyes with the number of ranibizumab injections for each group (P=0.391). CONCLUSION: Our study did not find an increased IOP in frequently-ranibizumab-treated eyes when compared to unfrequently-treated fellow control eyes. Further studies with a greater sample size are needed to evaluate whether an increased number of ranibizumab injections is associated with IOP changes. Dove Medical Press 2014-04-11 /pmc/articles/PMC3990463/ /pubmed/24748769 http://dx.doi.org/10.2147/OPTH.S58410 Text en © 2014 Yu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yu, Alice L
Seidensticker, Florian
Schaumberger, Markus
Welge-Lussen, Ulrich
Wolf, Armin
Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_full Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_fullStr Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_full_unstemmed Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_short Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
title_sort evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990463/
https://www.ncbi.nlm.nih.gov/pubmed/24748769
http://dx.doi.org/10.2147/OPTH.S58410
work_keys_str_mv AT yualicel evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab
AT seidenstickerflorian evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab
AT schaumbergermarkus evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab
AT welgelussenulrich evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab
AT wolfarmin evaluationofintraocularpressureelevationaftermultipleinjectionsofintravitrealranibizumab